{"product_id":"harrowinc-pestle-analysis","title":"Harrow PESTLE Analysis","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSkip the Research. Get the Strategy.\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eUnlock how political shifts, economic trends, and emerging technologies are reshaping Harrow’s outlook with our concise PESTLE snapshot—then dive deeper with the full analysis for actionable intelligence. Purchase the complete PESTLE to get detailed risks, opportunities, and ready-to-use insights for investors, strategists, and advisors.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eP\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eolitical factors\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eU.S. Healthcare Policy Shifts\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eThe ophthalmic pharmaceuticals market is shaped by federal priorities and the Inflation Reduction Act, which capped Medicare drug price growth and enabled negotiation saving CMS an estimated $104 billion through 2031; this raises pressure on specialty drug margins relevant to Harrow’s portfolio.\u003c\/p\u003e\n\u003cp\u003ePost-2025 leadership changes could drive stronger drug pricing transparency and accessibility mandates—recent proposals target average sales price reporting and Medicare price negotiations affecting ~20% of US prescription spending.\u003c\/p\u003e\n\u003cp\u003eHarrow must adapt pricing, payer strategies, and US commercial operations to protect revenue, given ophthalmology generics and biologics faced a 6–8% annual pricing compression in 2024–2025.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eMedicare Reimbursement Regulation\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cpa significant portion of harrow revenue at roughly in on medicare part b and d reimbursement schedules for eye care procedures prescriptions meaning cms fee schedule changes could shift annual by tens millions. policy adjustments have historically altered branded product uptake directly affecting adoption iheezo vevye. strategic lobbying rigorous compliance are essential to secure favorable coverage coding that protect rates market access.\u003e\n\u003c\/pa\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eFDA Approval Processes and Timelines\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cppolitical pressure to speed fda approvals for generics and novel ophthalmic drugs impacts harrow pipeline as the approved in reported initiatives cut review times by priority programs potentially altering launch timelines.\u003e\n\u003cpchanges to nda processes as revised user-fee timelines and proposed rulemaking shorten or extend time market average ophthalmic approval times range from months with generics often faster.\u003e\n\u003cpnavigating these regulatory and bureaucratic hurdles remains a core focus to protect harrow product portfolio revenue forecasts tied expected launches.\u003e\n\u003c\/pnavigating\u003e\u003c\/pchanges\u003e\u003c\/ppolitical\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eState-Level Pharmaceutical Legislation\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eState legislatures passed over 150 drug-pricing laws since 2019, with 2024 seeing ~28 new price-cap or cost-transparency measures that can reduce net drug revenues by 5–12% in affected states.\u003c\/p\u003e\n\u003cp\u003eHarrow must tailor compliance across ~50 state jurisdictions; localized legal teams and segmented pricing strategies are needed to manage uneven rebates, reporting, and marketing restrictions.\u003c\/p\u003e\n\u003cp\u003eFragmented rules complicate national distribution, raising logistics and admin costs by an estimated 3–6% and increasing time-to-market for formulary placements.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e150+ state laws since 2019; 28 new in 2024\u003c\/li\u003e\n\u003cli\u003ePotential 5–12% revenue impact per capped state\u003c\/li\u003e\n\u003cli\u003eCompliance and ops costs +3–6%\u003c\/li\u003e\n\u003cli\u003eRequires state-specific legal and pricing teams\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eTrade Policies and Supply Chain Security\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003ePolitical tensions and tariffs since 2022 have driven API import costs up roughly 12-18%, pushing manufacturers to seek domestic alternatives.\u003c\/p\u003e\n\u003cp\u003eUS reshoring incentives—$52B in CHIPS and biotech-related funding and 2024 tax credits—create both capital opportunities and operational challenges for Harrow to scale domestic production.\u003c\/p\u003e\n\u003cp\u003eSecuring supply chains amid geopolitical volatility is strategic for 2026, targeting \u0026gt;95% on-time API availability and multi-sourcing to limit disruption risk.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eAPI costs +12–18% since 2022\u003c\/li\u003e\n\u003cli\u003e$52B+ federal incentives supporting reshoring\u003c\/li\u003e\n\u003cli\u003eGoal: \u0026gt;95% on-time API availability via multi-sourcing\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePricing reforms, Medicare exposure and API cost squeeze reshape ophthalmic margins\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eFederal pricing reforms (IRA savings ~$104B thru 2031) and Medicare reliance (~45% of 2024 revenue) pressure specialty margins; state price caps (28 in 2024) can cut local net revenue 5–12%; FDA priority initiatives (53 novel approvals in 2024) may shorten ophthalmic launch timelines by ~15%; API costs +12–18% since 2022 vs $52B+ reshoring incentives—multi-sourcing targets \u0026gt;95% on-time API.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eMedicare revenue share (2024)\u003c\/td\u003e\n\u003ctd\u003e~45%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eIRA savings impact\u003c\/td\u003e\n\u003ctd\u003e$104B thru 2031\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eState price laws (2024)\u003c\/td\u003e\n\u003ctd\u003e28 new\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAPI cost rise since 2022\u003c\/td\u003e\n\u003ctd\u003e+12–18%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eExplores how external macro-environmental factors uniquely affect Harrow across Political, Economic, Social, Technological, Environmental, and Legal dimensions, with each section backed by current data and trends to identify threats and opportunities for executives, consultants, and entrepreneurs.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eA concise, shareable Harrow PESTLE summary that’s visually segmented by category for quick reference in meetings, editable for local context and easily dropped into presentations or strategy packs to streamline alignment and risk discussions.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eE\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003economic factors\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eInterest Rate Environment and Capital Access\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eAs of late 2025 Harrow faces a higher-rate legacy: US Fed funds around 5.25–5.50% and comparable global rates push borrowing costs up, raising weighted average cost of capital and constraining debt-funded licensing and clinical programs.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eInflationary Pressures on Manufacturing\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eRising costs for raw materials, specialized packaging and labor have compressed Harrow’s ophthalmic gross margins, with input inflation of 6–8% in 2024 and packaging cost increases of ~12% year-on-year reducing margins by an estimated 150–250 bps. The company faces pressure to pass on prices while competing with generics that grew to 28% market share in select ophthalmic segments in 2024. Maintaining operational efficiency—lean manufacturing, 5–7% productivity gains and supply-chain hedges—will be vital to offset persistent inflation and protect EBITDA. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHealthcare Spending and Disposable Income\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eEconomic health drives uptake of premium ophthalmic care: in the UK elective procedure spending fell 6% in 2023 amid real disposable income down 1.8% YoY, showing patients delay non-covered treatments; a consumer confidence drop of 12 points in 2023 correlated with higher uptake of generics—Harrow must price and position services for mixed-income cohorts, targeting resilient segments and flexible payment or financing options to retain demand.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eConsolidation in the Ophthalmic Market\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eEconomic pressures—managed care consolidation and M\u0026amp;A—are accelerating consolidation in ophthalmology: global ophthalmic M\u0026amp;A deal value reached about $11.2bn in 2024, raising buyer bargaining power and pressuring margins of small specialists like Harrow.\u003c\/p\u003e\n\u003cp\u003eHarrow must leverage its differentiated portfolio and specialty pipeline to remain a preferred supplier to large purchasers, protecting revenue by negotiating volume-based contracts and demonstrating cost-of-care benefits.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e2024 ophthalmic M\u0026amp;A: ~$11.2bn\u003c\/li\u003e\n\u003cli\u003eConsolidators increase purchasing leverage\u003c\/li\u003e\n\u003cli\u003eHarrow strategy: emphasize unique products, volume contracts, value data\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCurrency Exchange Volatility\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eFluctuations in the U.S. dollar alter costs of imported components and terms with international partners; USD strengthened ~8% vs. a trade-weighted basket in 2024, raising input costs for US-focused firms like Harrow.\u003c\/p\u003e\n\u003cp\u003eGlobal market instability can shift licensing payments tied to FX, with emerging-market currencies experiencing average 12-18% volatility versus USD in 2023–2024, increasing contractual risk.\u003c\/p\u003e\n\u003cp\u003eMonitoring FX trends is essential to manage supply-chain and logistics expenses: hedging reduced FX losses by 60% in sample tech firms in 2024.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eUSD strength up ~8% (2024) → higher import costs\u003c\/li\u003e\n\u003cli\u003eEmerging-market FX volatility 12–18% (2023–24) → licensing risk\u003c\/li\u003e\n\u003cli\u003eHedging cut FX losses ~60% in 2024\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRising rates, USD strength squeeze ophthalmic margins as M\u0026amp;A heats up\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eHigher global rates (Fed 5.25–5.50% in late 2025) and USD strength (~+8% in 2024) raise WACC and import costs; input inflation 6–8% (2024) and packaging +12% YY cut ophthalmic margins ~150–250 bps, while generics hit ~28% share. Elective spend down 6% (UK 2023) and real disposable income −1.8% (2023) pressure demand; global ophthalmic M\u0026amp;A ~$11.2bn (2024) increases buyer leverage.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eFed funds (late 2025)\u003c\/td\u003e\n\u003ctd\u003e5.25–5.50%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eUSD vs basket (2024)\u003c\/td\u003e\n\u003ctd\u003e+8%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eInput inflation (2024)\u003c\/td\u003e\n\u003ctd\u003e6–8%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePackaging increase (2024)\u003c\/td\u003e\n\u003ctd\u003e~12% YY\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGenerics share\u003c\/td\u003e\n\u003ctd\u003e~28%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eUK elective spend (2023)\u003c\/td\u003e\n\u003ctd\u003e−6%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOphthalmic M\u0026amp;A (2024)\u003c\/td\u003e\n\u003ctd\u003e$11.2bn\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003eFull Version Awaits\u003c\/span\u003e\u003cbr\u003eHarrow PESTLE Analysis\u003c\/h2\u003e\n\u003cp\u003eThe preview shown here is the exact Harrow PESTLE Analysis document you’ll receive after purchase—fully formatted, professionally structured, and ready to use, with no placeholders or teasers.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"MatrixBCG","offers":[{"title":"Default Title","offer_id":56751670165881,"sku":"harrowinc-pestle-analysis","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0911\/3554\/1625\/files\/harrowinc-pestle-analysis.png?v=1772233919","url":"https:\/\/matrixbcg.com\/products\/harrowinc-pestle-analysis","provider":"MatrixBCG","version":"1.0","type":"link"}